![](https://investorshub.advfn.com/uicon/441924.png?cb=1545404645)
Wednesday, May 27, 2015 8:17:17 AM
Milestone Scientific's Epidural & IA Subsidiary and Fidia Farmaceutici SpA Sign MOU for Co-Development and Manufacture of Custom Intra-Articular Drug Delivery Instrument
Milestone Scientific, Inc.
45 minutes ago
????
LIVINGSTON, NJ--(Marketwired - May 27, 2015) - Milestone Scientific Inc. (MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its Epidural & Intra-Articular (IA) Subsidiary has signed a Memorandum of Understanding (MOU) with Fidia Farmaceutici SpA, a specialty pharmaceutical company based in Italy, for the co-development and manufacture of a custom intra-articular drug delivery instrument for Fidia's hyaluronic acid formulations. Fidia is a leading producer of hyaluronic acid formulations for joint pain.
Under the terms of the MOU, upon completion of Fidia's evaluation of the technology, Milestone Scientific's Epidural & IA subsidiary and Fidia plan to enter into a co-development and manufacturing agreement. The goal is to develop a dedicated instrument and related disposables in order to optimize drug delivery and reduce pain associated with hyaluronic acid injections for joint pain. The custom instrument will be designed to deliver Fidia's selected hyaluronic acid products exclusively.
Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "Fidia Farmaceutici's focus on joint healthcare makes it an ideal partner for the intra-articular instrument, which has already received CE Mark marketing clearance in Europe. Fidia serves a large market and is one of the leading global manufacturers of hyaluronic acid formulations for intra-articular injections. Milestone's patented technologies have already demonstrated the ability to deliver painless injections. We look forward to working with Fidia as we believe our instrument will prove equally beneficial in reducing or eliminating the pain associated with the delivery of hyaluronic acid into the joints."
About Fidia Farmaceutici SpA
Fidia Farmaceutici SpA, a company belonging to the P&R Group, is a specialty pharmaceutical company whose mission, among others, is to provide, on a worldwide leadership position, whether directly or through its affiliated companies, patients with innovative products that offer quality, safety and high levels of performance. A primary focus of its product portfolio is "joint healthcare" for which it produces a number of hyaluronic acid formulations.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Klea Theoharis
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Recent MLSS News
- Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil • GlobeNewswire Inc. • 06/18/2024 03:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 06:11:22 PM
- Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:01:31 PM
- Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023 • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 03/28/2024 03:45:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio • GlobeNewswire Inc. • 02/28/2024 01:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:34:33 PM
- Milestone Scientific Inc. Announces Closing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/13/2023 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 05:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:21:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/12/2023 10:10:53 PM
- Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/11/2023 01:33:45 AM
- Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 12/08/2023 09:03:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/08/2023 09:00:28 PM
- Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures • GlobeNewswire Inc. • 12/08/2023 01:30:00 PM
- Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain • GlobeNewswire Inc. • 11/28/2023 01:30:00 PM
- Milestone Scientific Achieves Revenue of $2.1 Million and Provides Business Update for the Third Quarter of 2023 • GlobeNewswire Inc. • 11/15/2023 12:00:00 PM
- Milestone Scientific Schedules Third Quarter 2023 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 11/10/2023 01:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York • GlobeNewswire Inc. • 11/09/2023 01:30:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM